Comparative Pharmacology
Head-to-head clinical analysis: IBRUTINIB versus IMBRUVICA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBRUTINIB versus IMBRUVICA.
IBRUTINIB vs IMBRUVICA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
Clinical Note
moderateIbrutinib + Digoxin
"Ibrutinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIbrutinib + Digitoxin
"Ibrutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIbrutinib + Deslanoside
"Ibrutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIbrutinib + Acetyldigitoxin
"Ibrutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
None Documented
None Documented
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Terminal elimination half-life is approximately 4–6 hours. No clinically relevant accumulation is observed at steady state.
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Primarily via feces (approximately 80% as metabolites and parent drug); renal excretion accounts for <10% of the dose.
Category D/X
Category C
BTK Inhibitor
BTK Inhibitor